Sensus Healthcare (NASDAQ:SRTS) Posts Earnings Results, Misses Estimates By $0.41 EPS

Sensus Healthcare (NASDAQ:SRTS) released its quarterly earnings results on Thursday. The company reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.41), FiscalAI reports. The firm had revenue of $2.29 million for the quarter, compared to analyst estimates of $4.60 million. Sensus Healthcare had a negative return on equity of 15.79% and a negative net margin of 34.50%.

Here are the key takeaways from Sensus Healthcare’s conference call:

• Negative Sentiment: Second-quarter revenue fell to $2.3 million from $7.3 million year over year, while adjusted EBITDA was negative $3.0 million and net loss widened to $8.7 million, including a $5.7 million deferred-tax valuation allowance.
• Positive Sentiment: Management said financing delays prevented recognition of eight additional units in Q2, but those systems were subsequently approved and sold at an expected average selling price near $250,000; the related revenue is expected in Q3.
• Positive Sentiment: The company reported a stronger pipeline following education around new CPT codes, with increasing interest from independent practices, larger physician groups, and health systems. Management expects unit volume to rise sequentially, targeting more than 20 units in both Q3 and Q4.
• Positive Sentiment: Recurring-revenue initiatives are gaining traction, with the Fair Deal Agreement and outright purchases running at roughly a 50/50 mix. Sensus Link adoption is expanding among new and existing customers and is viewed as a high-margin software growth opportunity.
• Positive Sentiment: International expansion, particularly in Australia, New Zealand, China, and Hong Kong, is generating increased interest, while a proposed 26% increase in the relevant hospital physician fee schedule could further support SRT economics.

Sensus Healthcare Price Performance

Sensus Healthcare stock traded up $0.03 during mid-day trading on Thursday, reaching $3.16. 64,082 shares of the company were exchanged, compared to its average volume of 66,017. The company has a fifty day simple moving average of $2.94 and a 200-day simple moving average of $3.67. Sensus Healthcare has a 12 month low of $2.66 and a 12 month high of $5.49. The firm has a market cap of $52.01 million, a PE ratio of -6.72 and a beta of 1.10.

Institutional Trading of Sensus Healthcare

Several large investors have recently modified their holdings of the stock. Greenline Wealth Management LLC acquired a new position in Sensus Healthcare during the 4th quarter worth approximately $513,000. Rothschild Wealth LLC acquired a new stake in Sensus Healthcare in the fourth quarter valued at approximately $500,000. Ingalls & Snyder LLC acquired a new stake in Sensus Healthcare in the fourth quarter valued at approximately $219,000. Jane Street Group LLC bought a new stake in shares of Sensus Healthcare during the fourth quarter worth $79,000. Finally, XTX Topco Ltd bought a new stake in shares of Sensus Healthcare during the fourth quarter worth $77,000. 25.30% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

SRTS has been the topic of several recent research reports. Wall Street Zen cut Sensus Healthcare from a “sell” rating to a “strong sell” rating in a research report on Saturday, May 9th. Citigroup restated a “buy” rating on shares of Sensus Healthcare in a research note on Friday, May 8th. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Sensus Healthcare in a research report on Friday, July 17th. Three investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $6.75.

About Sensus Healthcare

Sensus Healthcare, Inc is a medical technology company specializing in the development, manufacture and commercialization of superficial radiation therapy (SRT) systems. The company’s SRT devices utilize low-energy X-rays to treat a range of dermatological and oncological conditions, most notably non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as benign lesions including keloids. By delivering targeted radiation to superficial tissue layers, Sensus Healthcare’s systems aim to provide an alternative to surgical excision or systemic therapies, offering clinicians a non-invasive treatment option for eligible patients.

The company’s flagship products include the SRT-100™ and SRT-100+™ platforms, which feature handheld applicators, adjustable energy settings and integrated safety controls.